Cambridge, MA-based Metamark Genetics said today it had entered into a research agreement with Janssen Biotech, a unit of New Brunswick, NJ-based Johnson & Johnson (NYSE: [[ticker:JNJ]]). Metamark, which was founded in 2007 on science from the Dana-Farber Cancer Institute, is developing prognostic tests based on genes discovered to play a role in how tumors progress and … Continue reading “Metamark Inks Potential $365M Deal with J&J For Cancer Marker Discovery”
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
Coronado Biosciences Debuts on Nasdaq, Moves Two Lead Drugs Forward
The path to becoming a publicly listed company chosen by Coronado Biosciences (NASDAQ: [[ticker:CNDO]]) was anything but conventional, but it seems to be working for the biotech startup. After raising $47.4 million privately over the last year, the company filed a Form 10 with the SEC so it could become a public company by registering all … Continue reading “Coronado Biosciences Debuts on Nasdaq, Moves Two Lead Drugs Forward”
Xconomy’s NY Venture Forum to Feature Insights From Gilt
Alexandra Wilkis Wilson, co-founder and chief merchandising officer of Gilt Groupe, knows a thing or two about attracting venture capital. Gilt—which holds limited time, online “flash” sales of clothing, accessories, and travel offerings—was founded in 2007 and raised $80 million in several rounds of financing. Then, in May of this year, Gilt raised an incredible … Continue reading “Xconomy’s NY Venture Forum to Feature Insights From Gilt”
Cerulean Pharma Adds $15M to Further Nano-Drug Platform
Cambridge, MA-based Cerulean Pharma announced today that it has raised $15 million in a Series D financing round, which included one new investor: CVF, an affiliate of Henry Crown and Company. Also participating in this round were existing investors Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. Cerulean’s lead drug candidate, … Continue reading “Cerulean Pharma Adds $15M to Further Nano-Drug Platform”
AesRx Navigates “Valley of Death” to Get Sickle Cell Drug Into Trials
Last week, Newton, MA-based AesRx announced that it has begun human trials of its lead drug, Aes-103, to treat sickle cell disease. To biotech observers, this may not have seemed like a big deal—sickle cell is a rare disease that affects only about 75,000 people in the U.S.—but for AesRx CEO Stephen Seiler, just getting … Continue reading “AesRx Navigates “Valley of Death” to Get Sickle Cell Drug Into Trials”
Merck Chemists Use High-Tech Science to Combat Alzheimer’s Disease Challenge
At an R&D and business briefing meeting that Merck (NYSE: [[ticker:MRK]]) held for Wall Street analysts at its Whitehouse Station, NJ, headquarters in November, the drug giant generated quite a bit of buzz for a drug that’s still several years away from market. That’s because the drug, called MK-8931, may offer a completely new way … Continue reading “Merck Chemists Use High-Tech Science to Combat Alzheimer’s Disease Challenge”
Zipmark Grabs $2M to Develop Mobile Payment System
New York-based startup Zipmark has raised $2 million in seed funding, according to a press release. Village Ventures and Contour Venture Partners led the funding round, which also included NYC Seed, High Peaks Venture Partners, and several angel investors. One of the other investors in this round was the New York City Investment Fund, which … Continue reading “Zipmark Grabs $2M to Develop Mobile Payment System”
Avila Shows Progress in Covalent Cancer Drugs at Prominent ASH Confab
Boston-based Avila Therapeutics announced data today from early human trials of its lead cancer drug, AVL-292, which the company is presenting at the American Society of Hematology (ASH) annual meeting in San Diego. The results support the company’s plans to move the drug into more extensive Phase 2 trials next year, says CEO Katrine Bosley. … Continue reading “Avila Shows Progress in Covalent Cancer Drugs at Prominent ASH Confab”
Fab.com Raises $40M from Andreessen Horowitz, Ashton Kutcher
Just five months after raising $8 million in a Series A funding round, New York-based daily-deals site Fab.com announced it has brought in a $40 million Series B. The funding was led by Andreessen Horowitz, with participation from existing investors Menlo Ventures, First Round Capital, Baroda Ventures, SoftTech VC, and actor Ashton Kutcher’s A-Grade Investments. … Continue reading “Fab.com Raises $40M from Andreessen Horowitz, Ashton Kutcher”
Everyday Health is Out to Dominate Media via Video, Apps, and Social
When dot-com entrepreneurs Benjamin Wolin and Michael Keriakos founded Everyday Health in 2002, everyone thought they were nuts. Their idea was to take well-known offline brands in the health industry and give them an online presence—a strategy that during the depths of the dot-com bust seemed mighty risky. “When we told people we wanted to … Continue reading “Everyday Health is Out to Dominate Media via Video, Apps, and Social”
Momenta Gets a Steal on Promising Scientific Asset from Once-Hot Virdante
When Cambridge, MA-based Momenta Pharmaceuticals said Monday that it had acquired the scientific assets of neighboring Virdante Pharmaceuticals (NASDAQ: [[ticker:MNTA]]), few paid much attention, perhaps because of the deal’s small size. Momenta paid just $4.5 million up front, plus additional milestone payments that could reach $51.5 million over time. But it appears that Momenta is … Continue reading “Momenta Gets a Steal on Promising Scientific Asset from Once-Hot Virdante”
Biogen Idec Boosts Biogenerics Strategy With $300M Samsung Joint Venture
[Updated 12/6/11 10:35 am. See below.] Today Biogen Idec (NASDAQ: [[ticker:BIIB]]) and Seoul, Korea-based conglomerate Samsung announced that they are teaming up to develop and market biosimilars—low-cost versions of biotech drugs that are losing their patent protection. The two companies will form a joint venture, based in Korea, which will be funded by $255 million from … Continue reading “Biogen Idec Boosts Biogenerics Strategy With $300M Samsung Joint Venture”
EnVivo Posts Positive Trial of Schizophrenia Drug
Watertown, MA-based EnVivo Pharmaceuticals presented results from a Phase 2b study of its schizophrenia compound, EVP-6124, today at the American College of Neuropsychopharmacology meeting in Hawaii. The drug demonstrated statistically significant improvements in cognitive function—the study’s main endpoint—the company said in a statement. Improvements were also observed in so-called negative symptoms of the disease—the inability … Continue reading “EnVivo Posts Positive Trial of Schizophrenia Drug”
Health Startups And Bigwigs Crowd Into First NYC Health IT Showcase
For two days last week, the New York eHealth Collaborative (NYeC) hosted presentations and exhibits from 43 companies eager to show off their health IT initiatives. The gathering attracted big names like UnitedHealth and GE, as well as nine startups seeking to make a name in health IT. The organizers of NYeC were stunned by … Continue reading “Health Startups And Bigwigs Crowd Into First NYC Health IT Showcase”
Regeneron Debuts Eye Drug, as Rivals Race to Grab Share of Hot Market
The folks at Regeneron (NASDAQ: [[ticker:REGN]]) had plenty to be thankful for the Friday before Thanksgiving, when late in the day, the FDA approved aflibercept (Eylea), the Tarrytown, NY-based biotech company’s drug to treat age-related macular degeneration, the leading cause of blindness in elderly people. It was a happy ending to a long and sometimes frustrating … Continue reading “Regeneron Debuts Eye Drug, as Rivals Race to Grab Share of Hot Market”
Harvard Bioscience Tool Used in First Transplants of Synthetic Tracheae
How does a 110-year-old medical device company end up on the cutting edge of regenerative medicine? The answer: A little innovation and a lot of persistence. That formula paid off this week for Holliston, MA-based Harvard Bioscience (NASDAQ: [[ticker:HBIO]]). On Monday, the company announced that a product it makes called the InBreath Bioreactor was featured … Continue reading “Harvard Bioscience Tool Used in First Transplants of Synthetic Tracheae”
Startups and VCs to Gather for Xconomy’s New York Venture Emergence Forum
Silicon Valley may get the lion’s share of attention when it comes to tech and biotech startups, but as has been clear since well before we launched Xconomy New York in April, the Big Apple has plenty to brag about, too. Take, for example, Gilt Groupe, the fashion e-commerce site that has raised more than … Continue reading “Startups and VCs to Gather for Xconomy’s New York Venture Emergence Forum”
Roche Embraces Three-Way Rare-Disease Play With PTC and Patient Group
Yesterday, European drug giant Roche and South Plainfield, NJ-based PTC Therapeutics announced they had entered into a drug-development pact that could be worth as much as $490 million to PTC. Such alliances are nothing new, especially these days, when Big Pharma companies are increasingly looking towards their smaller rivals for innovations. But this deal is … Continue reading “Roche Embraces Three-Way Rare-Disease Play With PTC and Patient Group”
CircuLite Pulls in $30M for Heart Device
Saddle Brook, NJ-based CircuLite announced today that it has raised $30 million in an oversubscribed Series D financing round. The company said in a statement that it will use the proceeds to support the anticipated 2012 European launch of a device it dubs “the world’s smallest surgically implanted blood pump,” which is used to treat … Continue reading “CircuLite Pulls in $30M for Heart Device”
Rib-X Pharma Files for IPO
New Haven, CT-based Rib-X Pharmaceuticals announced today that it has filed a registration statement with the SEC for an initial public offering. The company, which is developing antibiotics, has yet to determine the number of shares it will offer or the price range. Deutsche Bank Securities will manage the offering, with assistance from William Blair … Continue reading “Rib-X Pharma Files for IPO”
AlloCure Stem Cell Trial Provides Glimpse of Promising Treatment for Kidney Damage
Ever since nephrologist Robert Brenner joined Burlington, MA-based AlloCure in 2010, he’s been eager to find out how the company’s experimental stem-cell treatment for acute kidney injury would perform in people. Last week, he got his first hint of the answer—and it was a positive one. On Nov. 12, AlloCure presented results from a Phase … Continue reading “AlloCure Stem Cell Trial Provides Glimpse of Promising Treatment for Kidney Damage”
Aileron CEO Hails Expanded Roche Deal as a Validation of Stapled-Peptide Drug Technology
Yesterday, Cambridge, MA-based Aileron Therapeutics announced that a collaboration it had formed with European drug giant Roche in 2010 has been expanded. The companies, which have been working together on two programs focused on turning Aileron’s “stapled peptide” technology into cancer treatments, have now added a third program focused on inflammatory diseases. The financial details … Continue reading “Aileron CEO Hails Expanded Roche Deal as a Validation of Stapled-Peptide Drug Technology”
Agios Nabs $78M From Partner Celgene, Existing VCs, and Public Funds
Cambridge, MA-based Agios said today it has secured $78 million in an oversubscribed Series C financing. Included in this round are Agios’s drug-development partner Celgene (NASDAQ: [[ticker:CELG]]), along with existing investors Arch Venture Partners, Flagship Ventures, and Third Rock Ventures. The company also attracted several new investors that it did not name, except to say … Continue reading “Agios Nabs $78M From Partner Celgene, Existing VCs, and Public Funds”
Allena Pharma Launches With $15M From Third Rock and Other Top-Tier VCs
Allena Pharmaceuticals, based in Newton, MA, is announcing today that it has started up and raised $15 million in a Series A financing round, led by Third Rock Ventures, Frazier Healthcare, and Bessemer Venture Partners. The new company is pursuing protein therapeutics and is especially focused on kidney and urologic diseases. Its management team is … Continue reading “Allena Pharma Launches With $15M From Third Rock and Other Top-Tier VCs”
Avaxia Pulls in $2M from Angels to Fund Development of Cow-Derived Drug
The phrase “pharmaceutical manufacturing” doesn’t generally evoke visions of dairy farms. But it does for Barbara Fox, co-founder and CEO of Lexington, MA-based Avaxia Biologics, which is developing a drug derived from cow’s milk. And she’s succeeding in getting investors to share her vision: On November 10, Avaxia announced that it had closed $2.2 million … Continue reading “Avaxia Pulls in $2M from Angels to Fund Development of Cow-Derived Drug”
Turnaround CEO Shores Up Strategy for Unigene Based on Big Pharma Partnerships
When Ashleigh Palmer joined Boonton, NJ-based biotech company Unigene Laboratories as CEO in mid-2010, he faced a turnaround challenge that others might have considered way too daunting. The 30-year-old company was struggling to make money from a disjointed set of assets, which included a promising but, in Palmer’s view, under-marketed technology that could be used … Continue reading “Turnaround CEO Shores Up Strategy for Unigene Based on Big Pharma Partnerships”
Genzyme MS Drug Significantly Reduces Relapse, Disability in Late-Stage Trial
Cambridge, MA-based Genzyme, owned by French drug giant Sanofi (NYSE: [[ticker:SNY]]) said today its experimental drug to treat multiple sclerosis, alemtuzumab (Lemtrada), reduced relapse rates by 49 percent and dropped the risk of sustained worsening of disabilities by 42 percent in patients treated in a pivotal, Phase 3 trial. The drug was tested in a … Continue reading “Genzyme MS Drug Significantly Reduces Relapse, Disability in Late-Stage Trial”
Merck Unveils Alzheimer’s and Diabetes Projects, Personnel Changes
Merck (NYSE: [[ticker:MRK]]) outlined progress on several of the drugs in its pipeline today during its annual R&D and business briefing for Wall Street analysts and investors, which was held at the drug giant’s Whitehouse Station, NJ headquarters. CEO Kenneth Frazier began the day by acknowledging that Wall Street has been impatient with the company’s progress … Continue reading “Merck Unveils Alzheimer’s and Diabetes Projects, Personnel Changes”
Dusa Eyes Market Expansion for Skin Therapy Device
When Big Pharma veteran Robert Doman joined tiny Wilmington, MA-based Dusa Pharmaceuticals (NASDAQ: [[ticker:DUSA]]) in 2005, he found a company struggling to capitalize on a massive market opportunity. Dusa had won FDA approval in 2000 for a drug-device combination to treat actinic keratoses (AK), pre-cancerous skin growths. There are about 5 million cases of AKs treated … Continue reading “Dusa Eyes Market Expansion for Skin Therapy Device”
PharmaSecure Combats Drug Counterfeiting, Armed With Funding From Eric Schmidt’s Innovation Endeavors
Nathan Sigworth was studying economics at Dartmouth College a few years back when he became fascinated with the problem of counterfeit drugs in developing countries. Plenty of technology had been developed to combat counterfeits—RFID tagging and the like—but it wasn’t affordable enough to be scaled up in places like India. “The technology that was out … Continue reading “PharmaSecure Combats Drug Counterfeiting, Armed With Funding From Eric Schmidt’s Innovation Endeavors”
The Stroke Prevention War is On: FDA Approves J&J/Bayer Contender
Late Friday, the FDA approved rivaroxaban (Xarelto), a blood-thinning drug made by New Brunswick, NJ-based Johnson & Johnson (NYSE: [[ticker:JNJ]]) and Bayer. The approval came just two months after an advisory panel to the FDA posted a negative review of the drug, which suggested the companies should have to perform new trials to gain approval … Continue reading “The Stroke Prevention War is On: FDA Approves J&J/Bayer Contender”
NPS Charts Positive Results on Parathyroid Drug
NPS Pharmaceuticals’ (NASDAQ: [[ticker:NPSP]]) wild week continues today with the release of Phase 3 trial results on NPSP558, its experimental drug to treat hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone. The study shows that in 53 percent of patients, the drug achieved its treatment endpoint, namely that patients were able to halve … Continue reading “NPS Charts Positive Results on Parathyroid Drug”
AMAG Shares Zoom on CEO Departure and Re-Org Plans
Today, during its third-quarter earnings announcement, Lexington, MA-based AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]) announced the departure of its CEO, Brian Pereira, and a restructuring plan designed to decrease its operating expenses. Wall Street applauded, pushing the embattled company’s shares up 18 percent to $16.21.The news came just a couple of weeks after shareholders voted down Amag’s plan to … Continue reading “AMAG Shares Zoom on CEO Departure and Re-Org Plans”
Xconomists of the Week: Tom Maniatis and Marc Tessier-Lavigne Lead the Charge on the New York Genome Center
Today marked the official launch of the New York Genome Center, a collaboration among 11 top academic institutions that’s designed to accelerate genomic research. The initiative—supported by the City of New York and private and public institutions—is being guided by two of our Xconomists: Rockefeller University’s Marc Tessier-Lavigne, who will serve on the center’s board … Continue reading “Xconomists of the Week: Tom Maniatis and Marc Tessier-Lavigne Lead the Charge on the New York Genome Center”
NPS Pharma’s Not-So-Excellent Wall Street Adventure
On Monday morning, the phones were ringing off the hook at NPS Pharmaceuticals’ (NASDAQ: [[ticker:NPSP]]) Bedminster, N.J. headquarters, but no one could hear them. The freak autumn snowstorm over the weekend knocked out the company’s phone lines. And CEO Francois Nader and other top executives had lost power at their nearby homes, so they couldn’t charge … Continue reading “NPS Pharma’s Not-So-Excellent Wall Street Adventure”
New York Genome Center to Open in February, Supported by $125M in Public and Private Funding
A few days after Xconomy New York debuted in April, famed biotech pioneer and Columbia University professor Tom Maniatis gave us a preview of the New York Genome Center, a proposed coalition of academic institutions coming together to support genomics research in the city. His vision is now reality: The Center officially launches tomorrow with … Continue reading “New York Genome Center to Open in February, Supported by $125M in Public and Private Funding”
Alnylam and Glaxo Partner on RNAi for Vaccine Production
Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) announced today that it has formed a collaboration deal with GlaxoSmithKline (NYSE: [[ticker:GSK]]) centered around an RNAi technology Alnylam developed to enhance vaccine production. The technology, called VaxiRNA, uses molecules called “small interfering RNAs” (siRNAs) to silent specific genes that limit the efficient growth of viruses in vaccine manufacturing … Continue reading “Alnylam and Glaxo Partner on RNAi for Vaccine Production”
Truveris Seeks the Truth in Pharmacy Benefit Claims
Anthony Loiacono was hunting around for startup ideas a couple of years back when he came across a statistic he had a hard time believing: Every two weeks, $12 billion worth of pharmacy claims flows through the health-insurance system, and not a single one of those claims is checked for accuracy before it’s paid. “People … Continue reading “Truveris Seeks the Truth in Pharmacy Benefit Claims”
Pacira Wins FDA Approval of Pain Drug, Cushioning Pain of 3Q Loss
Parsippany, N.J-based Pacira Pharmaceuticals (NASDAQ: [[ticker:PCRX]]) announced today that the FDA approved its long-acting form of a pain drug called bupivacaine, which Pacira brands as Exparel. The approval marked a positive end to a bruising drug-development saga that began a dozen years ago. It also brightened up Pacira’s otherwise so-so third-quarter earnings, which the company … Continue reading “Pacira Wins FDA Approval of Pain Drug, Cushioning Pain of 3Q Loss”
Report: Gilt Picking Up Troubled Daily Deals Site BuyWithMe
[Updated 10/28/11 2:00 p.m. See below.] According to BetaBeat, fashion site Gilt Groupe is in the final stages of acquiring its New York neighbor BuyWithMe, a daily deals site that made six acquisitions this year and expanded to Seattle—but then started showing signs of distress. Just last week, reports emerged that BuyWithMe, which started in Boston, … Continue reading “Report: Gilt Picking Up Troubled Daily Deals Site BuyWithMe”
Repligen Buys Novozymes Unit, Expanding Product Base and Manufacturing Capacity
After the stock market closed last night, Waltham, MA-based Repligen (NASDAQ: [[ticker:RGEN]]) announced that it will buy a Swedish unit of Novozymes A/S, the Danish maker of industrial-biotech products, for 17 million euros, or about $22.7 million cash, plus 5 million euros ($5.6 million) in potential milestone payments. The unit, called Novozymes Biopharma Sweden, makes … Continue reading “Repligen Buys Novozymes Unit, Expanding Product Base and Manufacturing Capacity”
Sloan-Kettering Spinoff Adjuvance Gains Traction For Vaccine Tech
It’s rare to see an entrepreneur cheering for a direct rival, but that’s exactly what’s been happening over the last week or so in New York. It started on October 18, when shares of Boston-based Agenus (NASDAQ: [[ticker:AGEN]]) jumped 65 percent to $4.43 on news that a GlaxoSmithKline (NYSE: [[ticker:GSK]]) malaria vaccine containing an ingredient that … Continue reading “Sloan-Kettering Spinoff Adjuvance Gains Traction For Vaccine Tech”
BIND and Selecta Pull in $50M from Russian Fund Seeking to Advance Nano-Drugs
Two Boston-area startups—both of which emanated from the lab of MIT bioengineer and entrepreneur Bob Langer—announced today that they secured $25 million a piece in funding from Rusnano, a $10 billion Russian Federation fund that supports nanotechnology startups. The money went to Watertown, MA-based Selecta Biosciences and Cambridge, MA-based BIND Biosciences. Each company also added … Continue reading “BIND and Selecta Pull in $50M from Russian Fund Seeking to Advance Nano-Drugs”
Cubist Says Adolor Deal Offers “Free Option on Billion-Dollar Program”
Lexington, MA-based Cubist Pharmaceuticals (NASDAQ: [[ticker:CBST]]) had its eye on Adolor (NASDAQ: [[ticker:ADLR]]) long before it announced it would acquire the Exton, PA-based company on Monday. But it wasn’t until drug giant GlaxoSmithKline (NYSE: [[ticker:GSK]]) pulled out of a co-promotion deal with Adolor in June that Cubist could finally pounce. Glaxo and Adolor were partnered on a … Continue reading “Cubist Says Adolor Deal Offers “Free Option on Billion-Dollar Program””
MPM-Backed Rhythm Advances Drug Programs in Diabetes and Obesity
When Boston-based Rhythm Pharmaceuticals started up in 2010 with a plan to develop drugs to address diabetes and obesity, the biotech world was littered with companies struggling to make a mark in those disease areas. San Diego based Arena Pharmaceuticals was fighting to produce data for the FDA showing its obesity drug was safe. Phenomix, … Continue reading “MPM-Backed Rhythm Advances Drug Programs in Diabetes and Obesity”
Imagen Biotech, Staffed With Eyetech Vets, Launches in NYC With Plan to Tackle Eye Diseases
Nearly a week after announcing its $40 million Series A financing, New York-based Imagen Biotech is still largely in stealth mode. But the startup’s chief medical officer, Matthew Feinsod, took a few minutes yesterday to talk with Xconomy about one of Imagen’s top priorities: finding new drugs to treat “dry” age-related macular degeneration (AMD), a … Continue reading “Imagen Biotech, Staffed With Eyetech Vets, Launches in NYC With Plan to Tackle Eye Diseases”
Biotech Funding in New York: We Have Some Catching Up to Do
According to figures released this morning by Dow Jones VentureSource, 21 NYC-area biotech startups have been funded so far this year, down from 28 by the end of the third quarter of 2010. The dollar amounts have dropped, too: VCs have invested just $200 million in New York biotechs so far this year, compared to … Continue reading “Biotech Funding in New York: We Have Some Catching Up to Do”
Catabasis Begins Human Trials of Omega-3-Inspired Diabetes Treatment
After Jill Milne and Michael Jirousek left their positions at Sirtris Pharmaceuticals in 2008, they decided to pursue a titillating but still largely unproven idea: that fighting inflammation might help control Type 2 diabetes. On October 5, their startup, Cambridge, MA-based Catabasis Pharmaceuticals, began to test that theory in humans for the first time, with … Continue reading “Catabasis Begins Human Trials of Omega-3-Inspired Diabetes Treatment”
Arteaus, With $18M From Atlas and OrbiMed, Forges Ahead on Migraine-Prevention Drug
Cambridge, MA-based Arteaus Therapeutics is emerging from stealth mode today, announcing it is has raised an $18 million funding round and is developing a molecule licensed from drug giant Eli Lilly (NYSE: [[ticker:LLY]]) to prevent migraine headaches. The financing came from Cambridge, MA-based Atlas Venture and New York-based OrbiMed Advisors. Arteaus was founded in June, says … Continue reading “Arteaus, With $18M From Atlas and OrbiMed, Forges Ahead on Migraine-Prevention Drug”
Agenus Rejoices Over Positive Trial of Partner Glaxo’s Malaria Vaccine
Today European drug giant GlaxoSmithKline (NYSE: [[ticker:GSK]]) announced that the prestigious New England Journal of Medicine published results from a late-stage trial of its malaria vaccine, which showed that the vaccine provided significant protection against the disease in young African children. The results were announced in Seattle at a forum hosted by the Bill & … Continue reading “Agenus Rejoices Over Positive Trial of Partner Glaxo’s Malaria Vaccine”